Similarly, the MyD88 inhibitor TJ-M2010-2 suppresses the proliferation, migration, and invasion of breast cancer cells by intervening in the MyD88/GSK-3β and MyD88/NF-κB signaling pathways (33). Here, NFKB1 is linked to breast cancer.